By Lesli Skolarus, M.D., M.S.
Associate Professor, Neurology, University of Michigan
Sarah Bailey, M.A.
Executive Director, Bridges into the Future, Flint, MI
Post-stroke disability is substantially reduced by acute stroke treatments, which include intravenous tissue plasminogen activator (tPA) and intra-arterial treatment. Unfortunately, these treatments are underutilized—administered to less than 5 percent of U.S. stroke patients. Treatment with tPA must be given in the emergency department (ED) within 4.5 hours of the start of stroke symptoms. 1 The main reason stroke patients do not receive tPA is that they wait too long to call 911. 2 Think of tPA like Drano® for your brain: We want to get the plugged pipe—in the case of stroke, the plugged artery—open as soon as possible. The less time the artery is plugged, the lower the chance of brain damage, so it is extremely important that a person who is experiencing stroke symptoms calls 911 right away.
Compared with non-Hispanic Whites, African Americans are less likely to receive acute stroke treatment, largely due to their greater delays in seeking medical attention 3-7 Thus, the ability to recognize stroke symptoms and respond immediately by calling 911 is crucial to reducing racial disparities in post-stroke disability. 8 In Flint, Michigan, a predominantly African American community, the rate of acute stroke treatment is half the national rate. 9 In fact, Flint has the lowest treatment rate of any region of its size in the country.
African Americans experience significantly worse post-acute stroke outcomes. Our goal is to reduce this disparity by developing accessible, effective stroke preparedness programs with the communities that are most in need. By combining theory-based public health approaches to address neurological disease, we hope to provide neurologists and community partners with a framework for approaching neurological disease and, ultimately, improving the lives of our patients.
- Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768-74.
- Kleindorfer D, Kissela B, Schneider A, et al. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study. Stroke. 2004;35:e27-29.
- Schwamm LH, Reeves MJ, Pan W, et al. Race/ethnicity, quality of care, and outcomes in ischemic stroke. Circulation. 2010;121:1492-501.
- Johnston SC, Fung LH, Gillum LA, et al. Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers: the influence of ethnicity. Stroke. 2001;32:1061-8.
- Hsia AW, Edwards DF, Morgenstern LB, et al. Racial disparities in tissue plasminogen activator treatment rate for stroke: a population-based study. Stroke. 2011;42:2217-21.
- Lichtman JH, Watanabe E, Allen NB, Jones SB, Dostal J, Goldstein LB. Hospital arrival time and intravenous t-PA use in US Academic Medical Centers, 2001-2004. Stroke. 2009;40:3845-50.
- Messé SR, Khatri P, Reeves MJ, et al. Why are acute ischemic stroke patients not receiving IV tPA? Results from a national registry. Neurology. 2016;87:1565-74.
- Burke JF, Freedman VA, Lisabeth LD, Brown DL, Haggins A, Skolarus LE. Racial differences in disability after stroke: results from a nationwide study. Neurology. 2014;83:390-7.
- Skolarus LE, Meurer WJ, Shanmugasundaram K, Adelman EE, Scott PA, Burke JF. Marked Regional Variation in Acute Stroke Treatment Among Medicare Beneficiaries. Stroke. 2015;46:1890-6.
- Skolarus LE, Zimmerman MA, Murphy J, et al. Community-based participatory research: a new approach to engaging community members to rapidly call 911 for stroke. Stroke. 2011;42:1862-6.
- Skolarus LE, Zimmerman MA, Bailey S, et al. Stroke ready intervention: community engagement to decrease prehospital delay. Journal of the American Heart Association. 2016;5:e003331.